Everything biobased: plastic, medicine, and fuel. It seems like a futuristic utopia. But for how long? A collaboration of researchers now proposes an idea to accelerate the development process. By ...
IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index. In the last three years, IBB has remained flat and significantly underperformed the S&P 500. For retail investors, we think ...
The U.S. has been adept at inventing The Next Big Thing, but sometimes stumbles when it comes to exploiting it. From cars to electronics, solar panels, and semiconductors, this pattern has been ...
Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...
Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...
The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment ...
Parabilis Medicines is ambitious, but it has Regeneron on its side already.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results